Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Stock-based Compensation (Tables)

Note 11 - Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

Option numbers are in (000’s)
						Six months ended June 30, 2022
		Options				Weighted average exercise price				Weighted average remaining contractual life (years)

Outstanding, beginning of period			15,112			$	4.61
Granted			5,625				1.23
Exercised			(14	)			1.08
Forfeited			(1,567	)			2.87
Outstanding, end of the period			19,156				3.76				6.5
Exercisable, end of the period			10,656				4.65				4.8
Vested and expected to vest, end of period			17,879				3.83				6.4

Option numbers are in (000’s)
						Six months ended June 30, 2021
		Options				Weighted average exercise price				Weighted average remaining contractual life (years)

Outstanding, beginning of period			11,942			$	4.97
Granted			3,156				4.55
Exercised			(67	)			2.39
Forfeited			(800	)			5.67
Outstanding, end of the period			14,231				4.88				6.9
Exercisable, end of the period			8,001				4.60				5.7
Vested and expected to vest, end of period			13,296				4.85				6.8

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

		Six months ended June 30, 2022				Six months ended June 30, 2021

Risk-free interest rate			2.07	%			0.43	%
Expected dividend yield			-				-
Expected volatility			82.9	%			80.8	%
Expected life of options (in years)		5				5
Grant date fair value		$	0.82			$	2.91

Schedule of Share-based Payment Award, Options, Grants in Period [Table Text Block]

Option numbers are in (000’s)		Six months ended June 30, 2022				Six months ended June 30, 2021
		Number of options				Number of options
Cliff vesting after one year anniversary			-				-
3 year vesting (50%-25%-25%)			425				430
4 year vesting (50%-16 2/3%-16 2/3%-16 2/3%)			5,200				2,726
Total stock options granted in the period			5,625				3,156

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

		Three months ended June 30,								Six months ended June 30,
		2022				2021				2022				2021

Research and development		$	537			$	998			$	1,483			$	2,376
General and administrative			242				1,166				1,810				6,431
		$	779			$	2,164			$	3,293			$	8,807